ERG245
ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology[1].
Product Specifications
UNSPSC
12352005
Target
Aminotransferases (Transaminases)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/erg245.html
Purity
99.49
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O
Molecular Formula
C17H15BrO3
Molecular Weight
347.20
References & Citations
[1]Lodi F, et al. BCAT1 inhibition affects CD8+ T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis[J]. bioRxiv, 2023: 2023.02. 25.530034.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
sc-416686-LAC 200 µL
β-Arrestin-2 Lentiviral Activation Particles (h)
Sign In for Pricing
View Details